These differential gut bacteria may promote adaptive immunity by regulating the homeostasis of the intestinal environment, improving the tumor microenvironment, and enhancing the antitumor effects of anti-PD-1/PD-L1 therapies. This evidence concerns the gene PDCD1 and neoplasm.